Business Wire

Panasonic Develops High-Power Blue WBC Technology to Revolutionize DDL Applications on Microfabrication

29.1.2020 09:11:00 EET | Business Wire | Press release

Share

On January 29, 2020, Panasonic Corporation announced it has succeeded in demonstrating the world's highest brightness blue laser. This has been achieved by using the wavelength beam combining (WBC) technology [1] on a direct diode laser (DDL) to produce a high quality output beam [2]. With this technology, power scaling is enabled while maintaining the beam quality by simply increasing the number of laser sources. This demonstration opens the door to laser intensities that could be two orders of magnitude higher than conventional blue laser systems. This technology will contribute to the emerging microfabrication processes, whose demand is expected to grow in industrial applications, such as in the automotive industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005907/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Wavelength Beam Combining (WBC) technology (Graphic: Business Wire)

The automotive industry is moving towards “electrification” and “miniaturization” while requiring “high rigidity,” “design flexibility” and “productivity.” Against this background, the anticipation for the microfabrication lasers that can process various kinds of materials such as copper, gold and plastic is building up. Especially, blue laser with a high optical absorption efficiency has a high demand in the field of copper fabrication for the automotive motors and batteries. Highly-productive processing requires a laser beam source that has both high output power and high beam quality.

In order to attain such a beam source, Panasonic started collaboration with TeraDiode, Inc. (TDI), a Massachusetts, U.S.-based company, in 2013, and since has been developing WBC technology which can combine multiple and different wavelengths into one combined beam. In 2014, Panasonic released LAPRISS; the world’s first laser welding robot system equipped with an infrared DDL using WBC technology*1. In 2017, the company acquired TDI as a wholly owned subsidiary*2 and started developing on the output-power optimization on WBC as well as shortening the wavelength.

The output power optimization of the high-beam-quality blue laser (wavelength band = 400 – 450nm) was realized by combining more than 100 emitters from multiple diode bars [3] with WBC technology.

This WBC technology combines the beams from multiple emitters at different wavelengths that are incident on the diffraction grating at angles corresponding to each wavelength. The resonator is then formed in between the shared partially-transparent mirror and each edge face of the emitters. As a result, the output beam has achieved a output of 135 W with a high beam quality of BPP [4] 1.5mm・mrad.

Going forward, Panasonic will develop a processing system that is equipped with this laser beam source, as well as the process optimization in laser processing.

Panasonic will hold exhibits and lecture sessions on our technical achievement at PHOTONICS WEST 2020 in San Francisco from February 1 to 6, 2020.*3

A part of this research and development includes the data obtained from a project – “Development of advanced laser processing with intelligence based on high-brightness and high-efficiency laser technologies (TACMI project)” – commissioned by the New Energy and Industrial Technology Development Organization (NEDO) of Japan.

[Applications] Laser processing (welding, cutting, etc.)

[Patents] Total of 571 patents both domestic and international (including pending applications)

Notes:
*1: Panasonic Corporation Topics
April 15th, 2014: Panasonic has Released a Laser Welding Robot System "LAPRISS"-Equipped with the world's first high-power direct diode laser
https://news.panasonic.com/jp/topics/2014/38440.html (In Japanese)
*2: Panasonic Corporation News Release
January 6th, 2017: Panasonic Acquires All Shares of U.S.-Based Industrial Laser Start-up TeraDiode, Inc.
https://news.panasonic.com/global/press/data/2017/01/en170106-3/en170106-3.html
*3: PHOTONICS WEST 2020, San Francisco, 1-6 February 2020

Glossary
[1] Wavelength Beam Combining (WBC) technology: The technology that combines the beams with different wavelengths that are emitted from the multiple DDLs (direct diode lasers) on a diffraction grating.

[2] Beam quality: An index indicates how easy it is to combine the beam. Higher beam quality has smaller diameter and highly collimate feature.

[3] Diode bar: A laser bar that has multiple emittance stripes (emitters) in an array configuration on a single semiconductor chip.

[4] BPP (Beam Parameter Products): This is defined as the product of the radius r0 of the beam waist at the focusing position multiplied by the half-value half-width θ of the beam divergence angle; BPP = r0xθ. The unit is expressed in [mm・mrad]. The smaller BPP is, the higher the beam quality becomes.

About Panasonic
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 87 associated companies worldwide, recording consolidated net sales of 8.003 trillion yen for the year ended March 31, 2019. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global.

Source: https://news.panasonic.com/global/press/data/2020/01/en200129-2/en200129-2.html

Related Links
Industrial Devices & Solutions - Panasonic
https://industrial.panasonic.com/ww

TeraDiode, Inc.
https://www.teradiode.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Manufacturing Innovation Division
Promotion & Engineering Planning Department
Panasonic Corporation
Email: midpress@ml.jp.panasonic.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye